BioMarin and n-Lorem partner to develop ASO treatment for ReNU syndrome
Go back to BioMarin and n-Lorem partner to develop ASO treatment for ReNU syndrome| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 64.84 -0.24 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.08 | 52 Week High | $108.96 | |||
| Open | $65.25 | 52 Week Low | $62.12 | |||
| Day High | $65.29 | P/E | N/A | |||
| Day Low | $64.64 | EPS | $-1.27 | |||
| Volume | 505,272 | |||||
